Juniper Genomics Launches with $4.6M for Advanced Embryo Screening

Juniper Genomics has emerged from stealth with $4.6 million in seed funding to commercialize what it describes as the first embryo screening test utilizing whole genome and transcriptome sequencing. The Canada-based company aims to transform IVF genetic testing by analyzing millions of genetic markers, representing a significant advancement over traditional screening platforms.

Company Ventures led the funding round, with participation from Innospark Ventures, MBX Capital, Amboy Street Ventures, Dria Ventures, and Blue Collective. The capital will support commercial expansion, team growth, and ongoing research partnerships as Juniper begins deployment to early adopter clinics across North America.

The company was founded by Jeremy Grushcow, PhD, JD (CEO), Carolyn Quinlan, MSc (VP of Bioethics), and Dr. Lee Shulman (Medical Director). Their platform combines whole genome and transcriptome sequencing with trio analysis that includes both biological parents, screening for specific genetic changes linked to IVF failure, miscarriage, and medical conditions after birth.

"The IVF journey can be emotionally exhausting and financially overwhelming—and the current standard of care for embryo testing has a low success rate that often leaves patients with more questions than answers," said Grushcow. "We can do better by improving the chances of success on the very first try."

Juniper has taken a deliberate stance in the evolving embryo screening landscape by avoiding polygenic risk scores. The company focuses instead on specific genetic variants known to cause adverse pregnancy outcomes and serious health conditions. This approach contrasts with polygenic scores, which assess fewer than 1,000 data points and provide statistical associations rather than predictive outcomes for individual embryos.

The testing process seamlessly integrates into existing IVF workflows through standard day 5 or 6 embryo biopsies paired with parental blood draws. Juniper's comprehensive analysis examines thousands of clinically relevant genetic variants, positioning the test as a replacement for multiple existing preimplantation genetic testing methods.

"Juniper is addressing one of the most emotionally and financially challenging aspects of healthcare with a solution that is both scientifically advanced and deeply compassionate," said Margaret Davidson, Principal at Company Ventures. "Their approach has the potential to establish a new benchmark in IVF."

The platform enters an increasingly competitive embryo screening market where companies are expanding beyond basic chromosome analysis to include complex trait assessment. Juniper's emphasis on comprehensive genetic analysis while avoiding controversial polygenic scoring represents a distinctive approach to expanding embryo selection capabilities.

Beyond private investment, the company has secured support from Genome Canada and Genome Quebec GAPP grant funding, demonstrating both public and private sector interest in advancing embryo screening technology while maintaining ethical standards in reproductive medicine. This dual support underscores the recognized need for innovation in IVF success rates alongside responsible implementation of genetic screening technologies.

Click here for the original news story.